CY1112579T1 - Μεθοδοι και συνθεσεις για τη διαγνωση του ηλικιακου εκφυλισμου της ωχρας κηλιδας - Google Patents
Μεθοδοι και συνθεσεις για τη διαγνωση του ηλικιακου εκφυλισμου της ωχρας κηλιδαςInfo
- Publication number
- CY1112579T1 CY1112579T1 CY20121100030T CY121100030T CY1112579T1 CY 1112579 T1 CY1112579 T1 CY 1112579T1 CY 20121100030 T CY20121100030 T CY 20121100030T CY 121100030 T CY121100030 T CY 121100030T CY 1112579 T1 CY1112579 T1 CY 1112579T1
- Authority
- CY
- Cyprus
- Prior art keywords
- diagnosis
- amd
- sunglasses
- compositions
- methods
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 4
- 208000002780 macular degeneration Diseases 0.000 abstract 4
- 102000016550 Complement Factor H Human genes 0.000 abstract 2
- 108010053085 Complement Factor H Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62936304P | 2004-11-18 | 2004-11-18 | |
| US64947905P | 2005-02-02 | 2005-02-02 | |
| US67234605P | 2005-04-18 | 2005-04-18 | |
| EP05851755A EP1836312B1 (en) | 2004-11-18 | 2005-11-18 | Methods and compositions for diagnosing age-related macular degenration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112579T1 true CY1112579T1 (el) | 2016-02-10 |
Family
ID=36578383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100030T CY1112579T1 (el) | 2004-11-18 | 2012-01-11 | Μεθοδοι και συνθεσεις για τη διαγνωση του ηλικιακου εκφυλισμου της ωχρας κηλιδας |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20090017029A1 (enExample) |
| EP (1) | EP1836312B1 (enExample) |
| JP (2) | JP2008520242A (enExample) |
| KR (1) | KR101290621B1 (enExample) |
| CN (2) | CN101142321B (enExample) |
| AT (1) | ATE528410T1 (enExample) |
| AU (1) | AU2005314461B2 (enExample) |
| BR (1) | BRPI0518289A2 (enExample) |
| CA (1) | CA2588270A1 (enExample) |
| CY (1) | CY1112579T1 (enExample) |
| DK (1) | DK1836312T3 (enExample) |
| ES (1) | ES2375490T3 (enExample) |
| IL (1) | IL183284A (enExample) |
| WO (1) | WO2006062716A2 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2505786C (en) | 2002-11-25 | 2011-06-21 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| CN103505728A (zh) | 2005-05-26 | 2014-01-15 | 科罗拉多大学评议会法人机构 | 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制 |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| DK2500030T4 (en) * | 2005-11-04 | 2018-10-29 | Genentech Inc | Use of complement pathway inhibitors for the treatment of eye diseases |
| WO2007120975A2 (en) * | 2006-02-13 | 2007-10-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Variants in complement regulatory genes predict age-related macular degeneration |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| EP1989319A4 (en) * | 2006-02-13 | 2009-11-11 | Univ Iowa Res Found | VARIANTS OF COMPLEMENTARY REGULATOR GENES AS FORECAST FOR AGE-RELATED MACULAR GENERATION |
| JP5250548B2 (ja) | 2006-06-21 | 2013-07-31 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 疾患の治療のための補体ｈ因子の標的化 |
| DK2447275T3 (en) * | 2006-07-13 | 2015-06-29 | Univ Iowa Res Found | Methods and reagents for the treatment of age-related macular degeneration |
| AU2016204271B2 (en) * | 2006-07-13 | 2018-04-19 | University Of Iowa Research Foundation | Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration |
| MX2009000909A (es) * | 2006-07-26 | 2009-02-04 | Univ Yale | Diagnostico y tratamiento de degeneracion macular relacionada con la edad. |
| CN101173314B (zh) * | 2006-10-18 | 2010-12-01 | 四川省医学科学院（四川省人民医院） | 检测老年黄斑变性疾病的试剂盒 |
| CN106084055A (zh) | 2006-11-02 | 2016-11-09 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| GB0701213D0 (en) * | 2007-01-23 | 2007-02-28 | Univ Cardiff | Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration |
| US7972787B2 (en) | 2007-02-16 | 2011-07-05 | Massachusetts Eye And Ear Infirmary | Methods for detecting age-related macular degeneration |
| WO2008140653A2 (en) | 2007-03-14 | 2008-11-20 | Taligen Therapeutics, Inc. | Humaneered anti-factor b antibody |
| JP5226256B2 (ja) * | 2007-07-26 | 2013-07-03 | ニプロ株式会社 | 加齢黄斑変性症の発症リスクの予測方法 |
| WO2009059317A2 (en) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715 |
| US8114592B2 (en) | 2008-03-18 | 2012-02-14 | Cambridge Enterprise Limited | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof |
| WO2009121065A2 (en) * | 2008-03-28 | 2009-10-01 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| KR101719376B1 (ko) * | 2008-11-05 | 2017-03-23 | 제넨테크, 인크. | 연령-관련 황반 변성에서 유전자 다형성 |
| WO2010075519A2 (en) * | 2008-12-23 | 2010-07-01 | Massachusetts Eye & Ear Infirmary | Allelic variants associated with advanced age-related macular degeneration |
| KR100937720B1 (ko) * | 2009-04-20 | 2010-01-20 | 전남대학교산학협력단 | ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법 |
| JP5871798B2 (ja) | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 肝再生を刺激する方法 |
| CN102958535A (zh) | 2009-11-05 | 2013-03-06 | 亚力史剑桥公司 | 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗 |
| EP2533797A1 (en) | 2010-02-12 | 2012-12-19 | CeMM Forschungszentrum für Molekulare Medizin GmbH | Complement factor h for oxidative stress disease conditions |
| MX2012013233A (es) | 2010-05-14 | 2013-05-20 | Univ Colorado Regents | Grupos que apuntan a receptor 2 de complemento (cr2) mejorados. |
| US8809517B2 (en) * | 2010-06-01 | 2014-08-19 | University Of Kentucky Research Foundation | Method of inhibiting Alu RNA and therapeutic uses thereof |
| BR112012033119A2 (pt) | 2010-06-22 | 2016-10-25 | Univ Colorado Regents | anticorpos para o fragamento c3d do componente do complemento 3. |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| JP2014502953A (ja) | 2010-08-16 | 2014-02-06 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 細胞透過性治療薬の鼻腔内送達 |
| FR2983212A1 (fr) * | 2011-11-28 | 2013-05-31 | Lfb Biotechnologies | Aptameres anti-fh, procede pour leur obtention et utilisations |
| FR2988298A1 (fr) * | 2012-03-23 | 2013-09-27 | Lfb Biotechnologies | Facteur h pour son utilisation comme molecule antioxydante |
| US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
| CN102707068B (zh) * | 2012-05-31 | 2015-03-18 | 北京大学 | 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| US10035822B2 (en) | 2012-11-15 | 2018-07-31 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| WO2014151923A1 (en) | 2013-03-14 | 2014-09-25 | Baxter International Inc. | Factor h for treatment of rheumatoid arthritis |
| EP2968457B1 (en) | 2013-03-14 | 2018-08-29 | Baxalta Incorporated | Factor h for transplantation |
| JP5721150B2 (ja) * | 2013-03-14 | 2015-05-20 | 学校法人 埼玉医科大学 | 加齢黄斑変性症の発症リスクの予測方法 |
| AU2013202965B2 (en) | 2013-03-15 | 2016-07-21 | Takeda Pharmaceutical Company Limited | Improved method for producing factor h from a plasma precipitation fraction |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| MX2016001854A (es) | 2013-08-12 | 2016-09-06 | Genentech Inc | Composiciones y metodo para tratar condiciones asociadas con el complemento. |
| US20150093331A1 (en) * | 2013-10-01 | 2015-04-02 | OncoLock Co., Ltd. | Biomarkers for breast cancer |
| KR102131973B1 (ko) * | 2013-12-30 | 2020-07-08 | 주식회사 케이티 | 개인 건강관리 방법 및 시스템 |
| CN107207585B (zh) * | 2014-02-26 | 2021-12-21 | 阿勒根公司 | 补体组分c5抗体 |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| SG11201608868PA (en) | 2014-05-01 | 2016-11-29 | Genentech Inc | Anti-factor d antibody variants and uses thereof |
| KR102314785B1 (ko) * | 2015-04-21 | 2021-10-19 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 마커 및 황반변성 진단방법 |
| KR20180090785A (ko) | 2015-10-07 | 2018-08-13 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 |
| TW201730211A (zh) | 2015-10-30 | 2017-09-01 | 建南德克公司 | 抗因子d抗體及結合物 |
| JP2018536650A (ja) | 2015-10-30 | 2018-12-13 | ジェネンテック， インコーポレイテッド | 抗ｄ因子抗体変異体コンジュゲート及びその使用 |
| CN105334328B (zh) * | 2015-11-01 | 2017-03-22 | 深圳市艾伟迪生物科技有限公司 | 一种用于检测眼科疾病的试剂盒及其检测方法 |
| KR20210157427A (ko) * | 2015-12-03 | 2021-12-28 | 리제너론 파마슈티칼스 인코포레이티드 | 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법 |
| KR102011182B1 (ko) * | 2016-10-07 | 2019-08-16 | 단국대학교 천안캠퍼스 산학협력단 | 익상편 과발현 유전자 및 이의 용도 |
| BR112019020955A2 (pt) | 2017-04-07 | 2020-05-05 | Apellis Pharmaceuticals, Inc. | regimes de dosagem e composições e métodos relacionados |
| JP2021507884A (ja) | 2017-12-15 | 2021-02-25 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 投与レジメンならびに関連組成物および方法 |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2020019002A1 (en) | 2018-07-20 | 2020-01-23 | University Of Utah Research Foundation | Gene therapy for macular degeneration |
| WO2020180147A2 (ko) * | 2019-03-07 | 2020-09-10 | (주)레티마크 | 나이관련 황반변성 진단용 복합 마커 및 이의 용도 |
| WO2021158589A1 (en) * | 2020-02-04 | 2021-08-12 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors |
| KR102333953B1 (ko) * | 2020-07-10 | 2021-12-02 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 유전자 마커 |
| EP4001301A1 (en) * | 2020-11-13 | 2022-05-25 | Navigo Proteins Gmbh | Binding protein for complement factor h (cfh) |
| CN113293206A (zh) * | 2021-07-23 | 2021-08-24 | 西安医臻生物医药科技有限公司 | 一种快速鉴别老年黄斑病变风险的方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA2336703A1 (en) * | 1998-07-10 | 2000-01-20 | The University Of Sydney | Prophylactic treatments of neovascularisation in macular degeneration |
| US20020032319A1 (en) * | 2000-03-07 | 2002-03-14 | Whitehead Institute For Biomedical Research | Human single nucleotide polymorphisms |
| DK1287364T3 (da) * | 2000-04-29 | 2009-03-02 | Univ Iowa Res Found | Diagnostisk og terapi til makulære degenerationsrelaterede lidelser |
| CN1466953A (zh) * | 2003-01-15 | 2004-01-14 | 哈佛东方生物医药（云南）有限公司 | 预防治疗老年黄斑变性的复合制剂 |
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
-
2005
- 2005-11-18 CA CA002588270A patent/CA2588270A1/en not_active Abandoned
- 2005-11-18 CN CN2005800467319A patent/CN101142321B/zh not_active Expired - Fee Related
- 2005-11-18 AT AT05851755T patent/ATE528410T1/de active
- 2005-11-18 BR BRPI0518289-1A patent/BRPI0518289A2/pt not_active IP Right Cessation
- 2005-11-18 KR KR1020077013736A patent/KR101290621B1/ko not_active Expired - Fee Related
- 2005-11-18 ES ES05851755T patent/ES2375490T3/es not_active Expired - Lifetime
- 2005-11-18 WO PCT/US2005/041664 patent/WO2006062716A2/en not_active Ceased
- 2005-11-18 DK DK05851755.8T patent/DK1836312T3/da active
- 2005-11-18 US US11/791,025 patent/US20090017029A1/en not_active Abandoned
- 2005-11-18 EP EP05851755A patent/EP1836312B1/en not_active Expired - Lifetime
- 2005-11-18 AU AU2005314461A patent/AU2005314461B2/en not_active Ceased
- 2005-11-18 JP JP2007543226A patent/JP2008520242A/ja not_active Withdrawn
- 2005-11-18 CN CN2012100868621A patent/CN102618644A/zh active Pending
-
2007
- 2007-05-17 IL IL183284A patent/IL183284A/en not_active IP Right Cessation
-
2011
- 2011-09-16 US US13/235,289 patent/US20120135000A1/en not_active Abandoned
-
2012
- 2012-01-04 JP JP2012000185A patent/JP2012080900A/ja active Pending
- 2012-01-11 CY CY20121100030T patent/CY1112579T1/el unknown
-
2013
- 2013-09-26 US US14/038,602 patent/US20140018306A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1836312T3 (da) | 2012-03-12 |
| HK1113690A1 (en) | 2008-10-10 |
| US20140018306A1 (en) | 2014-01-16 |
| EP1836312A2 (en) | 2007-09-26 |
| KR20070105969A (ko) | 2007-10-31 |
| JP2008520242A (ja) | 2008-06-19 |
| IL183284A (en) | 2014-09-30 |
| WO2006062716A3 (en) | 2006-10-05 |
| US20120135000A1 (en) | 2012-05-31 |
| ATE528410T1 (de) | 2011-10-15 |
| BRPI0518289A2 (pt) | 2008-11-11 |
| KR101290621B1 (ko) | 2013-07-29 |
| CN101142321B (zh) | 2012-06-06 |
| ES2375490T3 (es) | 2012-03-01 |
| AU2005314461A1 (en) | 2006-06-15 |
| JP2012080900A (ja) | 2012-04-26 |
| IL183284A0 (en) | 2007-09-20 |
| WO2006062716A2 (en) | 2006-06-15 |
| AU2005314461B2 (en) | 2012-02-02 |
| CA2588270A1 (en) | 2006-06-15 |
| CN101142321A (zh) | 2008-03-12 |
| EP1836312B1 (en) | 2011-10-12 |
| CN102618644A (zh) | 2012-08-01 |
| US20090017029A1 (en) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1836312T3 (da) | Fremgangsmåder og sammensætninger til diagnosticeringer af aldersrelateret makulær degeneration | |
| ATE440536T1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
| MA29528B1 (fr) | Agents de fixation | |
| MX2017008904A (es) | Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerotica. | |
| EP2498095A3 (en) | Use of IGFBP-7 in the assessment of heart failure | |
| MY143215A (en) | Multifocal lenses for pre-presbyopic individuals | |
| ATE424560T1 (de) | Marker für neuromyelitis optica | |
| DOP2011000052A (es) | Metodo de identificacion de factores de riesgo de la enfermedad | |
| GB0117326D0 (en) | Napthoquinone-type inhibitors of protein aggregation | |
| HUP0301877A2 (hu) | Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek | |
| ATE526041T1 (de) | Verfahren zur hemmung okularer vorgänge | |
| DE602007008235D1 (de) | Verfahren zur verarbeitung von biomedizinischen bildern | |
| WO2010041046A8 (en) | Granin proteins as markers of heart disease | |
| BRPI0417732A (pt) | aplicação de gene amilóide a sérico no diagnóstico e tratamento do glaucoma e identificação de agentes antiglaucoma | |
| WO2005098433A3 (en) | Diagnostic assays for alzheimer’s disease | |
| EP2189541A3 (en) | Methods and reagents for treatment and diagnosis of age-related macular degeneration | |
| WO2006036943A3 (en) | Determination of molecular age by detection of ink4a/arf expression | |
| WO2007000349A3 (en) | Optical imaging of rheumatoid arthritis | |
| DE602004029061D1 (de) | Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes | |
| WO2005113831A3 (en) | Biomarkers for multiple sclerosis and methods of use thereof | |
| DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| ATE456797T1 (de) | Verwendung von nogo-c bei der beurteilung von herzversagen | |
| WO2006002240A8 (en) | Computer systems and methods for constructing biological classifiers and uses thereof | |
| Okazi et al. | Comparison of Attitude of Physicians and Patients About Euthanasia in Tehran’s University of Medical Sciences Hospitals in 2012-2013 | |
| WO2006032021A3 (en) | Identification of gene associated with reading disability and uses therefor |